Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

abstract：PURPOSE:RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models. The objective of this analysis is to examine the pharmacokinetic (PK) results from four Phase I studies that have been conducted with RO5323441 (n = 61) and to report an...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang K,Stark FS,Schlothauer T,Lahr A,Cosson V,Zhi J,Habben K,Tessier J,Schick E,Staack RF,Krieter O

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND:The pharmacokinetics and tissue distribution of photofrin II (PF) and its efficacy in sonodynamic therapy were studied in rats bearing AH130 solid tumors. MATERIALS AND METHODS:In order to find the optimum timing of the ultrasound exposure after administration of PF, the PF concentrations in plasma, skin, m...

journal_title：Cancer chemotherapy and pharmacology

authors： Yumita N,Umemura S

更新日期：2003-02-01 00:00:00

abstract：BACKGROUND:Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific tra...

journal_title：Cancer chemotherapy and pharmacology

authors： Trojel-Hansen C,Erichsen KD,Christensen MK,Jensen PB,Sehested M,Nielsen SJ

更新日期：2011-07-01 00:00:00

abstract：:This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alon...

journal_title：Cancer chemotherapy and pharmacology

authors： Frustaci S,Grattoni E,Tumolo S,Crivellari D,Figoli F,Galligioni E,Veronesi A,Tirelli U,Grigoletto E

更新日期：1986-01-01 00:00:00

abstract：BACKGROUND:Few clinical phase II studies using non-platinum doublet as adjuvant chemotherapy following complete resection of non-small-cell lung cancer (NSCLC) have been published, so this clinical study was designed to evaluate the toxicity profile and efficacy of the non-platinum doublet of docetaxel (DOC) + gemcitab...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawamura M,Eguchi K,Izumi Y,Yamato Y,Koike T,Sakaguchi H,Hada E,Kobayashi K

更新日期：2007-09-01 00:00:00

abstract：:A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they rea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pollera CF,Ameglio F,Reina S,Nardi M,Abbolito MR,Parracino C

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:We have developed and evaluated a CNS-targeted chemotherapy regimen based on the pharmacokinetic properties of the individual drugs in the combination. PATIENTS AND METHODS:In a twin-track study, 16 patients with secondary CNS lymphoma (SCNSL) and 8 with primary CNS lymphoma (PCNSL) were treated with IDARAM wh...

journal_title：Cancer chemotherapy and pharmacology

authors： Moreton P,Morgan GJ,Gilson D,Smith GM,McVerry BA,Davies JM,Mackie MJ,Bolam S,Jalihal SS,Howard MR,Parapia LA,Williams AT,Child JA,Central and Southern Lymphoma Group.

更新日期：2004-04-01 00:00:00

abstract：PURPOSE:To investigate the activity of combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin in patients with metastatic urothelial cancer. METHODS:A group of 29 patients were treated with 2000 mg/m2 ifosfamide, 750 mg/m2 5-fluorouracil, 100 mg/m2 etoposide and 20 mg/m2 cisplatin. All four ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukui I,Yonese J,Tsukamoto T,Yoshida T,Kim T,Tohma T,Ishiwata D

更新日期：2001-07-01 00:00:00

abstract：:The pharmakokinetic profiles of intraperitoneally infused platinum analogues were determined in 13 women exhibiting minimal residual disease following surgery and systemic chemotherapy for epithelial ovarian cancer or fallopian tube carcinoma by following the disposition of tracer doses of 195mPt radiolabel. Six patie...

journal_title：Cancer chemotherapy and pharmacology

authors： Lind MJ,Murphy DJ,Sharma H,Tinker N,Smith A,McAuliffe CA,Crowther D

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:2-Methoxyestradiol (2-ME) is a physiological metabolite of estrogen, which can inhibit growth of many types of tumor cells, including hepatocellular carcinoma, both in vitro and in vivo. The exact mechanisms of its action are still unclear. We have studied the mechanisms of growth inhibition of several of human...

journal_title：Cancer chemotherapy and pharmacology

authors： Kar S,Wang M,Carr BI

更新日期：2008-10-01 00:00:00

abstract：OBJECTIVE:To investigate the effects of FSTL1-mediated NF-κB signaling pathway on cisplatin (DDP) sensitivity of EOC cells. METHODS:FSTL1 expression was determined in epithelial ovarian cancer (EOC) tissues and corresponding adjacent tissues using immunohistochemistry. SKOV3 and SKOV3/DDP cells were transfected and gr...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu YK,Jia YJ,Liu SH,Ma J

更新日期：2021-01-03 00:00:00

abstract：PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

更新日期：2002-09-01 00:00:00

abstract：PURPOSE:The purpose of these extensive non-clinical studies was to assess pharmacokinetics and dispositional properties of sunitinib and its primary active metabolite (SU12662). METHODS:Sunitinib was administered in single and repeat oral doses in mice, rats, and monkeys. Assessments were made using liquid-chromatogra...

journal_title：Cancer chemotherapy and pharmacology

authors： Haznedar JO,Patyna S,Bello CL,Peng GW,Speed W,Yu X,Zhang Q,Sukbuntherng J,Sweeny DJ,Antonian L,Wu EY

更新日期：2009-09-01 00:00:00

abstract：:Etoposide has been used in the treatment of a wide variety of neoplasms, including small-cell lung cancer, Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicit...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi K,Ratain MJ

更新日期：1994-01-01 00:00:00

abstract：:Taxol is the prototype of a class of antineoplastic drugs that target microtubules. It enhances tubulin-monomer polymerization and stabilizes tubulin polymers, increasing the fraction of cells in the G2 or M phase of the cell cycle. We report that treatment of HL-60 and U937 myeloid cell lines with 1-10 microM taxol i...

journal_title：Cancer chemotherapy and pharmacology

authors： Gangemi RM,Tiso M,Marchetti C,Severi AB,Fabbi M

更新日期：1995-01-01 00:00:00

abstract：:To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen PG,Nissen MH,Groth S,Rørth M

更新日期：1985-01-01 00:00:00

abstract：:The local therapeutic effects and 5-year survival rates obtained following subsegmental transcatheter arterial embolization (TAE) therapy for small hepatocellular carcinomas (HCCs) were retrospectively analyzed. A total of 124 nodular-type HCC lesions measuring less than 4 cm in diameter in 100 patients with liver cir...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsui O,Kadoya M,Yoshikawa J,Gabata T,Takashima T,Demachi H

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:The diatomic radical nitric oxide (NO) has been the cause of intense debate with implication in carcinogenesis, tumour progression, invasion, angiogenesis and modulation of therapeutic responses. The tumour biology of NO is highly complex, and this review summarises the various protective and damaging mode of a...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh S,Gupta AK

更新日期：2011-06-01 00:00:00

abstract：:The discovery of targetable mutations, which cause gene rearrangement, led to a major advancement in the treatment of patients with non-small cell lung cancer (NSCLC), and cancers with such mutations can be paired with drugs which specifically target them. c-ros oncogene (ROS1) positive NSCLC is one molecular subtype ...

journal_title：Cancer chemotherapy and pharmacology

authors： Roys A,Chang X,Liu Y,Xu X,Wu Y,Zuo D

更新日期：2019-10-01 00:00:00

abstract：:The ability of the polysulfonated antitumor drug suramin and six related polysulfonated azo dyes to inhibit the cell growth, platelet-derived growth factor (PDGF)-receptor binding, and intracellular Ca2+ signaling of Swiss 3T3 fibroblasts was studied. Some of the azo dyes were more potent inhibitors of PDGF binding th...

journal_title：Cancer chemotherapy and pharmacology

authors： Powis G,Seewald MJ,Melder D,Hoke M,Gratas C,Christensen TA,Chapman DE

更新日期：1992-01-01 00:00:00

abstract：:Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

journal_title：Cancer chemotherapy and pharmacology

authors： Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

更新日期：2004-01-01 00:00:00

abstract：:A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Gillies H,Liang R,Rogers H,Harper P,Parapia L,Cox G,Johnson S

更新日期：1988-01-01 00:00:00

abstract：:Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response t...

journal_title：Cancer chemotherapy and pharmacology

authors： Rubens RD,King RJ,Sexton S,Minton MJ,Hayward JL

更新日期：1980-01-01 00:00:00

abstract：PURPOSE:P-glycoprotein (P-gp), encoded by MDR1 (or ABCB1), is important in anticancer drug delivery and resistance. We evaluated alterations in P-gp-mediated transport of anticancer agents due to the MDR1 G1199A polymorphism. METHODS:Using stable recombinant epithelial cells expressing wild-type (MDR1 (wt)) or G1199A ...

journal_title：Cancer chemotherapy and pharmacology

authors： Woodahl EL,Crouthamel MH,Bui T,Shen DD,Ho RJ

更新日期：2009-06-01 00:00:00

abstract：OBJECTIVES:The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. METHODS:The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion foll...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee J,Kim TY,Lee MA,Ahn MJ,Kim HK,Lim HY,Lee NS,Park BJ,Kim JS,Korean Cancer Study Group.

更新日期：2008-01-01 00:00:00

abstract：:Recent studies in human bone-marrow culture and healthy human volunteers suggest that lenograstim [glycosylated, recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Chinese hamster ovary (CHO) cells] has greater in vivo potency than filgrastim [nonglycosylated, methionine-extended recombinan...

journal_title：Cancer chemotherapy and pharmacology

authors： Nohynek GJ,Plard JP,Wells MY,Zerial A,Roquet F

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients. METHODS:Five dose level combinations with irinotecan (from 180 to 240 mg/m(2), day 1, q21), capecitabine (1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Bajetta E,Di Bartolomeo M,Buzzoni R,Ferrario E,Dotti KF,Mariani L,Bajetta R,Gevorgyan A,Venturino P,Galassi M

更新日期：2009-06-01 00:00:00

abstract：OBJECTIVES:To assess the cardiovascular safety, tolerability and efficacy of high doses of granisetron for the treatment of nausea and vomiting in patients undergoing highly emetogenic chemotherapy. METHODS:Patients with histologically confirmed malignant disease were given an intravenous infusion of granisetron, 160 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Carmichael J,Harris AL

更新日期：2004-02-01 00:00:00

abstract：PURPOSE:Acid ceramidase (AC) occupies an important place in the control of cancer cell proliferation. We tested the influence of AC inhibition on the effects of PSC 833, a P-glycoprotein antagonist with potent ceramide-generating capacity, to determine whether AC could be a therapeutic target in pancreatic cancer. MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Morad SA,Messner MC,Levin JC,Abdelmageed N,Park H,Merrill AH Jr,Cabot MC

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:An isolated pelvic perfusion technique using multiple agents was used both in patients with unresectable recurrent pelvic neoplasms and as a preoperative therapy for advanced pelvic malignancy. METHODS:The technique consisted of vascular occlusion via transfemoral balloon catheters, circulation and drug infusi...

journal_title：Cancer chemotherapy and pharmacology

authors： Wanebo HJ,Belliveau JF

更新日期：1999-01-01 00:00:00